Adalimumab alone and in combination with disease‐modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

OBJECTIVE: To evaluate the safety and effectiveness of adalimumab alone or in combination with standard disease‐modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA). METHODS: Patients with active RA despite treatment with DMARDs or prior treatment with a tumour necro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Burmester, Gerd R, Mariette, Xavier, Montecucco, Carlomaurizio, Monteagudo‐Sáez, Indalecio, Malaise, Michel, Tzioufas, Athanasios G, Bijlsma, Johannes W J, Unnebrink, Kristina, Kary, Sonja, Kupper, Hartmut
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2007
Teme:
Extended Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1954645/
https://ncbi.nlm.nih.gov/pubmed/17329305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2006.066761
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki